|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2009. CA Cancer J Clin. 59:225–249. 2009.
|
|
2
|
Wang D and Dubois RN: Prostaglandins and
cancer. Gut. 55:115–122. 2006.
|
|
3
|
Tai HH: Prostaglandin catabolic enzymes as
tumor suppressors. Cancer Metastasis Rev. 30:409–417. 2011.
|
|
4
|
Na HK, Park JM, Lee HG, et al:
15-Hydroxyprostaglandin dehydrogenase as a novel molecular target
for cancer chemoprevention and therapy. Biochem Pharmacol.
82:1352–1360. 2011.
|
|
5
|
Tai HH, Cho H, Tong M and Ding Y:
NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and
biological functions. Curr Pharm Des. 12:955–962. 2006.
|
|
6
|
Tatsuwaki H, Tanigawa T, Watanabe T, et
al: Reduction of 15-hydroxyprostaglandin dehydrogenase expression
is an independent predictor of poor survival associated with
enhanced cell proliferation in gastric adenocarcinoma. Cancer Sci.
101:550–558. 2010.
|
|
7
|
Wolf I, O’Kelly J, Rubinek T, et al:
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of
human breast cancer. Cancer Res. 66:7818–7823. 2006.
|
|
8
|
Pham H, Chen M, Li A, et al: Loss of
15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in
pancreatic tumors. Pancreas. 39:332–339. 2010.
|
|
9
|
Quidville V, Segond N, Lausson S, et al:
15-Hydroxyprostaglan- din-dehydrogenase is involved in
anti-proliferative effect of non-steroidal anti-inflammatory drugs
COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
Prostaglandins Other Lipid Mediat. 81:14–30. 2006.
|
|
10
|
Lou LH, Jing DD, Lai YX, et al: 15-PGDH is
reduced and induces apoptosis and cell cycle arrest in gastric
carcinoma. World J Gastroenterol. 18:1028–1037. 2012.
|
|
11
|
Tseng-Rogenski S, Gee J, Ignatoski KW, et
al: Loss of 15-hydroxyprostaglandin dehydrogenase expression
contributes to bladder cancer progression. Am J Pathol.
176:1462–1468. 2010.
|
|
12
|
Huang G, Eisenberg R, Yan M, et al:
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte
nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer
Res. 68:5040–5048. 2008.
|
|
13
|
Wakimoto N, Wolf I, Yin D, et al:
Nonsteroidal anti-inflammatory drugs suppress glioma via
15-hydroxyprostaglandin dehydrogenase. Cancer Res. 68:6978–6986.
2008.
|
|
14
|
Backlund MG, Mann JR, Holla VR, et al:
Repression of 15-hydroxyprostaglandin dehydrogenase involves
histone deacetylase 2 and snail in colorectal cancer. Cancer Res.
68:9331–9337. 2008.
|
|
15
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474.
2010.
|
|
16
|
Travis WD, Brambilla E, Müller-Hermelink
HK and Harris CC: Pathology & Genetics: Tumours of the Lung,
Pleura, Thymus and Heart. IARC Press; Lyon: pp. 26–44. 2004
|
|
17
|
Gou HF, Chen XC, Zhu J, et al: Expressions
of COX-2 and VEGF-C in gastric cancer: correlations with
lymphangiogenesis and prognostic implications. J Exp Clin Cancer
Res. 30:142011.
|
|
18
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991.
|
|
19
|
Ding Y, Tong M, Liu S, Moscow JA and Tai
HH: NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH)
behaves as a tumor suppressor in lung cancer. Carcinogenesis.
26:65–72. 2005.
|
|
20
|
Backlund MG, Mann JR, Holla VR, et al:
15-Hydroxyprostaglandin dehydrogenase is down-regulated in
colorectal cancer. J Biol Chem. 280:3217–3223. 2005.
|
|
21
|
Lim SC, Cho H, Lee TB, et al: Impacts of
cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and
cyclooxygenase-2 expressions on tumor progression in colorectal
cancer. Yonsei Med J. 51:692–699. 2010.
|
|
22
|
Liu Z, Wang X, Lu Y, et al: Expression of
15-PGDH is downregulated by COX-2 in gastric cancer.
Carcinogenesis. 29:1219–1227. 2008.
|
|
23
|
Tennis MA, Vanscoyk M, Keith RL and Winn
RA: The role of prostacyclin in lung cancer. Transl Res. 155:57–61.
2010.
|
|
24
|
Tong M, Ding Y and Tai HH: Reciprocal
regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin
dehydrogenase expression in A549 human lung adenocarcinoma cells.
Carcinogenesis. 27:2170–2179. 2006.
|
|
25
|
Krishnan AV, Swami S and Feldman D:
Vitamin D and breast cancer: inhibition of estrogen synthesis and
signaling. J Steroid Biochem Mol Biol. 121:343–348. 2010.
|
|
26
|
Lim K, Han C, Xu L, et al:
Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in
human cholangiocarcinoma cells: evidence for inhibition of these
signaling pathways by omega 3 polyunsaturated fatty acids. Cancer
Res. 68:553–560. 2008.
|
|
27
|
Lim K, Han C, Dai Y, Shen M and Wu T:
Omega-3 polyunsaturated fatty acids inhibit hepatocellular
carcinoma cell growth through blocking beta-catenin and
cyclooxygenase-2. Mol Cancer Ther. 8:3046–3055. 2009.
|
|
28
|
Sahin M1, Sahin E and Gümüslü S:
Cyclooxygenase-2 in cancer and angiogenesis. Angiology. 60:242–253.
2009.
|
|
29
|
Zhou D, Cheng SQ, Ji HF, et al: Evaluation
of protein pigment epithelium-derived factor (PEDF) and microvessel
density (MVD) as prognostic indicators in breast cancer. J Cancer
Res Clin Oncol. 136:1719–1727. 2010.
|
|
30
|
Qin LX and Tang ZY: Recent progress in
predictive biomarkers for metastatic recurrence of human
hepatocellular carcinoma: a review of the literature. J Cancer Res
Clin Oncol. 130:497–513. 2004.
|
|
31
|
Gulubova M and Vlaykova T: Prognostic
significance of mast cell number and microvascular density for the
survival of patients with primary colorectal cancer. J
Gastroenterol Hepatol. 24:1265–1275. 2009.
|
|
32
|
Aurello P, Bellagamba R, Rossi Del Monte
S, et al: Apoptosis and microvessel density in gastric cancer:
correlation with tumor stage and prognosis. Am Surg. 75:1183–1188.
2009.
|
|
33
|
Meert AP, Paesmans M, Martin B, et al: The
role of microvessel density on the survival of patients with lung
cancer: a systematic review of the literature with meta-analysis.
Br J Cancer. 87:694–701. 2002.
|
|
34
|
Luo H, Chen Z, Jin H, et al:
Cyclooxygenase-2 up-regulates vascular endothelial growth factor
via a protein kinase C pathway in non-small cell lung cancer. J Exp
Clin Cancer Res. 30:62011.
|
|
35
|
Huang SP, Wu MS, Shun CT, et al:
Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular
endothelial growth factor to promote angiogenesis in gastric
carcinoma. J Biomed Sci. 12:229–241. 2005.
|
|
36
|
Brecht K, Weigert A, Hu J, et al:
Macrophages programmed by apoptotic cells promote angiogenesis via
prostaglandin E2. FASEB J. 25:2408–2417. 2011.
|
|
37
|
Zhang B, Ma X, Li Z, et al: Celecoxib
enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene
therapy in treating murine breast cancer. J Cancer Res Clin Oncol.
139:797–807. 2013.
|
